pramlintide (Symlin)

a synthetic analogue of human amylin that helps regulate glucose

Also Known As:

Symlin; AC 0137; AC 137; LYS-CYS-ASN-THR-ALA-THR-CYS-ALA-THR-GLN-ARG-LEU-ALA-ASN-PHE-LEU-VAL-HIS-SER-SER-ASN-ASN-PHE-GLY-PRO-ILE-LEU-PRO-PRO-THR-ASN-VAL-GLY-SER-ASN-THR-TYR-NH2; Tripro-Amylin; pramlintide acetate

Networked: 219 relevant articles (36 outcomes, 71 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Weyer, Christian: 16 articles (10/2009 - 01/2002)
2.	Kolterman, Orville G: 10 articles (05/2013 - 01/2002)
3.	Weyer, C: 10 articles (09/2005 - 09/2001)
4.	Maggs, David G: 8 articles (01/2016 - 04/2002)
5.	Wang, Yan: 8 articles (07/2007 - 01/2003)
6.	Kolterman, O G: 7 articles (09/2015 - 09/2001)
7.	Heptulla, Rubina A: 7 articles (09/2014 - 04/2005)
8.	Lutz, Karen: 7 articles (05/2013 - 11/2003)
9.	Herrmann, Kathrin: 6 articles (01/2016 - 02/2007)
10.	Edelman, Steven V: 6 articles (05/2013 - 01/2002)

Related Diseases

1.	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 11/01/2009 - "The objective of this study was to evaluate the safety and efficacy of home pramlintide use in adolescents with type 1 diabetes. " 01/01/2016 - "Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials." 01/01/2013 - "Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes." 11/01/2009 - "A pilot trial of pramlintide home usage in adolescents with type 1 diabetes." 10/01/2008 - "Self-monitored BG (SMBG) records were retrospectively analyzed from a randomized, double-blind, placebo-controlled study of the effects of pramlintide on intensively treated patients with type 1 diabetes. "
2.	Type 2 Diabetes Mellitus (MODY) 01/01/2016 - "Cardiovascular safety of pramlintide was assessed using accepted regulatory medical definitions of AEs reported in five randomized, controlled phase 3 and 4 trials of 16-52 weeks' duration in adults with type 2 diabetes. " 01/01/2016 - "Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials." 10/01/2005 - "Five studies, also ranging from 4 to 52 weeks' duration, examined the effect of administering premeal pramlintide in patients with type 2 diabetes. " 01/01/2018 - "Pramlintide (Symlin®) is currently the only one being used clinically to treat type 1 and type 2 diabetes. " 02/01/2008 - "Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes."
3.	Weight Loss (Weight Reduction) 09/01/2008 - "When used over 12 months as an adjunct to LSI, pramlintide treatment, with low-dose three-times-daily or higher-dose two-times-daily regimens, helped obese subjects achieve greater initial weight loss and enhanced long-term maintenance of weight loss." 03/01/2010 - "Preliminary trials assessing the use of pramlintide for weight loss in obese patients without diabetes have demonstrated weight loss of up to 8 kg after 1 year. " 05/01/2005 - "The results indicate that enhanced satiety and reduced food intake may explain the weight loss observed in long-term pramlintide trials." 08/30/2010 - "pramlintide) result in weight loss. " 03/01/2010 - "To evaluate the weight-loss effects of pramlintide. "
4.	Body Weight (Weight, Body) 11/10/2012 - "In another study, Intravail® treated control mice gained 38.2% of their initial body weight, while mice receiving pramlintide acetate or [D-Leu-4]-OB3 were only 26.8% and 25.4% heavier, respectively, at the end of the study, Co-administration of pramlintide acetate and [D-Leu-4]-OB3 did not further enhance the effect of pramlintide acetate on body weight gain. " 03/01/2010 - "All studies conducted on humans and published in English that examined the effects of pramlintide on body weight as a primary or secondary endpoint were selected for analysis. " 04/01/2007 - "In two 52-week studies in patients with type 2 DM, the groups that received pramlintide 120 microg BID (n = 166) and 150 microg TID (n = 144) had respective 0.62% and 0.6% reductions in HbA(1c) and 1.4- and 1.3-kg reductions in body weight (all, P < 0.05 vs placebo). " 04/01/2007 - "In two 52-week studies in patients with type 1 DM, the groups that received pramlintide 30 to 60 microg QID (n = 243), 60 microg TID (n = 164), and 60 microg QID (n = 161) had respective 0.39%, 0.29%, and 0.34% reductions in HbA(1c) and 0.5-, 0.3-, and 0.6-kg reductions in body weight, respectively (all, P < 0.05 vs placebo). " 10/15/2021 - "In a separate experiment, the effects of central injection of pramlintide on food intake and body weight were similarly evaluated. "
5.	Hypoglycemia (Reactive Hypoglycemia) 12/01/2003 - "The glycemic improvement with pramlintide was not associated with an increased incidence of hypoglycemia over the entire study period (43% pramlintide v 40% placebo). " 01/01/2017 - "None of the participants developed hypoglycemia after the injection of pramlintide. " 01/01/2016 - "Event rates for severe hypoglycemia were similar for pramlintide and placebo and increased with longer duration of diabetes for both groups. " 04/01/2009 - "No hypoglycemia was reported in the first week of starting pramlintide. " 12/01/2007 - "We conclude that pramlintide bolus may result in an increase in risk of immediate postprandial hypoglycemia. "

Related Drugs and Biologics

1.	Insulin (Novolin)
2.	Islet Amyloid Polypeptide
3.	metreleptin
4.	Glucose (Dextrose)
5.	Hormones (Hormone)
6.	Glucagon (Glukagon)
7.	Glycated Hemoglobin (Glycosylated Hemoglobin)
8.	Exenatide (Byetta)
9.	Leptin
10.	Glucagon-Like Peptide 1 (GLP 1)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Insulin Infusion Systems
4.	Injections
5.	Subcutaneous Injections